Provenance Wealth Advisors’s Pfizer PFE Stock Holding History

Provenance Wealth Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$411K	Buy	17,084 +359	+2%	+$9.39K	0.04%	90
2026 Q1	$470K	Hold	16,725	–	–	0.05%	75
2025 Q4	$416K	Hold	16,725	–	–	0.05%	70
2025 Q3	$426K	Sell	16,725 -220	-1%	-$5.43K	0.06%	75
2025 Q2	$411K	Sell	16,945 -6,095	-26%	-$142K	0.06%	76
2025 Q1	$584K	Sell	23,040 -4,088	-15%	-$107K	0.08%	59
2024 Q4	$720K	Sell	27,128 -30,644	-53%	-$831K	0.09%	62
2024 Q3	$1.67M	Buy	57,772 +704	+1%	+$20.5K	0.21%	40
2024 Q2	$1.6M	Sell	57,068 -300	-0.5%	-$8.26K	0.22%	35
2024 Q1	$1.59M	Buy	57,368 +16,414	+40%	+$455K	0.22%	36
2023 Q4	$1.18M	Buy	40,954 +40,105	+4,724%	+$1.21M	0.16%	49
2023 Q3	$28.2K	Buy	+849	New	+$30K	﹤0.01%	206

Other funds holding PFE

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Provenance Wealth Advisors's PFE Position: Q2 2026 in Review

Provenance Wealth Advisors increased its Pfizer (PFE) stake by 2.1% in Q2 2026, buying an estimated $9.39K and bringing the position to 17,084 shares worth $411K. The position accounts for 0.04% of the portfolio, ranked #90.

Provenance Wealth Advisors first reported a position in PFE in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.67M in Q3 2024. 1,067 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Provenance Wealth Advisors held 17,084 shares of Pfizer worth $411K as of Q2 2026.
Provenance Wealth Advisors bought 359 Pfizer shares in Q2 2026, an estimated $9.39K.
Pfizer made up 0.04% of Provenance Wealth Advisors's portfolio in Q2 2026, its #90 holding.
Provenance Wealth Advisors first reported a position in Pfizer in Q3 2023 and has held it in 12 quarters since.
Provenance Wealth Advisors's Pfizer position peaked at $1.67M in Q3 2024.
1,067 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Provenance Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.